FOSS releases new version of Vision
8 November 2012 | By FOSS NIRSystems Inc.
FOSS NIRSystems, Inc. has introduced Vision 3.60. Vision is a software package specifically designed for use with the FOSS NIRSystems NIR laboratory & process analyzers...
List view / Grid view
News
Merck and Regenstrief Institute Establish Evidence-Based Care Collaboration
8 November 2012 | By Merck
The Regenstrief Institute and Merck have signed a five-year agreement...
Auxilium and Pfizer will conclude agreement on XIAPEX® EU collaboration
7 November 2012 | By Pfizer
Auxilium Pharmaceuticals, Inc., and Pfizer are amending their collaboration agreement...
Novartis drug Signifor® recommended by FDA advisory committee for approval to treat patients with Cushing’s disease
7 November 2012 | By Novartis
Committee votes unanimously in favor of Signifor (pasireotide)...
Novartis Phase III study shows RLX030 improved symptoms and reduced deaths by one-third in patients with acute heart failure
7 November 2012 | By Novartis
RELAX-AHF study met one of its two primary endpoints...
U.S. Food and Drug Administration approves Pfizer’s XELJANZ® (tofacitinib citrate)
6 November 2012 | By Pfizer
The U.S. FDA has approved XELJANZ®...
Takeda to acquire Envoy Therapeutics, Inc.
6 November 2012 | By
Gains innovative research platform-bacTRAP technology and adds novel CNS programs...
Janssen announces collaboration with Vertex on phase 2 study
5 November 2012 | By
To investigate an all-oral regimen of simeprevir (Tmc435) and Vx-135 for treatment of hepatitis C...
AMG 145 significantly reduced LDL cholesterol in patients
5 November 2012 | By
Results from RUTHERFORD study presented at American Heart Association Scientific Sessions 2012...
Pradaxa® – Development of antidote may expand range of methods to reverse anticoagulant effect during emergency situations
5 November 2012 | By Boehringer Ingelheim
New findings presented...
FDA and EMA reaffirm important health benefits and safety of Pradaxa® for patients with atrial fibrillation
5 November 2012 | By Boehringer Ingelheim
"We welcome the positive conclusions reached..."
Novartis drug Votubia® approved in the EU as first medication to treat patients with non-cancerous kidney tumors associated with TSC
5 November 2012 | By Novartis
European Commission approval for Votubia®...
IFPAC-2013: The Premier International Event on QbD and PAT
5 November 2012 | By IFPAC
IFPAC 2013, 22-25 January 2013, Baltimore Marriott Waterfront, Baltimore, Maryland, USA
Phase 3 Sensipar® / Mimpara® EVOLVE(TM) trial published in the New England Journal of Medicine
3 November 2012 | By Amgen
Study results presented at American Society of Nephrology's Kidney Week...
Merck will initiate interferon-free Phase II clinical trials for MK-5172
2 November 2012 | By Merck
Merck announced plans to initiate two new clinical trials with MK-5172...
